What's in the pipeline for the treatment of Parkinson's disease?
| Autor: | David B. Sommer, Mark Stacy |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Clinical Trials as Topic Parkinson's disease business.industry General Neuroscience Dopaminergic Parkinson Disease Disease medicine.disease Bioinformatics Neuroprotection Unmet needs Antiparkinson Agents Neuroprotective Agents Dyskinesia Drug development Medicine Humans Pharmacology (medical) Neurology (clinical) medicine.symptom business Psychiatry |
| Zdroj: | Expert review of neurotherapeutics. 8(12) |
| ISSN: | 1744-8360 |
| Popis: | Parkinson's disease (PD) is a common, debilitating neurodegenerative disorder that creates a significant burden for patients, family members and society at large. Major unmet needs include effective therapies that could favorably modify the underlying pathogenetic processes in PD, and better control of motor and nonmotor symptoms in advanced-stage disease. This review examines the current state of development of potential PD therapies, including dopaminergic therapies, modulators of adenosine and glutamate receptors, cell-based therapies, genetic therapies and device-based therapies. In addition, research into potential neuroprotective agents and pipeline therapies for nonmotor symptoms of PD are summarized. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|